XNASGLUE
Market cap350mUSD
Jan 10, Last price
5.70USD
1D
-4.84%
1Q
15.62%
IPO
-69.78%
Name
Monte Rosa Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-135m
L+29.38%
CFO
-44m
L-52.63%
Profile
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 149,533 | 120,943 | |||
Unusual Expense (Income) | |||||
NOPBT | (149,533) | (120,943) | |||
NOPBT Margin | |||||
Operating Taxes | 338 | (3,883) | |||
Tax Rate | |||||
NOPAT | (149,871) | (117,060) | |||
Net income | (135,352) 29.38% | (104,618) 45.42% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 27,492 | 20,466 | |||
BB yield | -9.47% | -5.69% | |||
| Debt | |||||
Debt current | 6,324 | 3,127 | |||
Long-term debt | 88,916 | 90,875 | |||
Deferred revenue | 32,323 | ||||
Other long-term liabilities | 2,713 | 1,533 | |||
Net debt | (137,173) | (173,142) | |||
| Cash flow | |||||
Cash from operating activities | (43,802) | (92,466) | |||
CAPEX | (19,041) | (12,911) | |||
Cash from investing activities | 88,801 | (219,219) | |||
Cash from financing activities | 27,492 | 20,466 | |||
FCF | (150,575) | (166,642) | |||
| Balance | |||||
Cash | 232,413 | 262,826 | |||
Long term investments | 4,318 | ||||
Excess cash | 232,413 | 267,144 | |||
Stockholders' equity | (368,607) | (232,283) | |||
Invested Capital | 632,094 | 552,230 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 51,397 | 47,227 | |||
Price | 5.65 -25.76% | 7.61 -62.73% | |||
Market cap | 290,393 -19.20% | 359,400 -62.18% | |||
EV | 153,220 | 186,258 | |||
EBITDA | (143,311) | (117,198) | |||
EV/EBITDA | |||||
Interest | 3,764 | ||||
Interest/NOPBT | |||||